Peroxisome Signaling Pathway in Neurodegeneration

Peroxisome Pathway in Neurodegeneration

Introduction

Peroxisome Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Peroxisomes are essential organelles involved in fatty acid β-oxidation, plasmalogen synthesis, [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) metabolism, andetherlipid formation. Peroxisomal dysfunction is increasingly recognized in neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Zellweger spectrum disorders. This pathway intersects with lipid metabolism, oxidative stress, and neuroinflammation. [@plasmalogens2009]

Pathway Diagram

Key Molecular Players

Peroxisome Pathway in Neurodegeneration

Introduction

Peroxisome Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Peroxisomes are essential organelles involved in fatty acid β-oxidation, plasmalogen synthesis, [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) metabolism, andetherlipid formation. Peroxisomal dysfunction is increasingly recognized in neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Zellweger spectrum disorders. This pathway intersects with lipid metabolism, oxidative stress, and neuroinflammation. [@plasmalogens2009]

Pathway Diagram

Key Molecular Players

| Component | Type | Function | [@plasmalogen2015]
|-----------|------|----------| [@pex2013]
| PEX1 | Gene/Protein | Peroxisome biogenesis factor 1, AAA-ATPase | [@peroxisome2010]
| PEX5 | Gene/Protein | Peroxisomal targeting signal receptor | [@acox2014]
| PEX6 | Gene/Protein | Peroxisome biogenesis, AAA-ATPase | [@peroxisomes2013]
| PEX10 | Gene/Protein | Peroxisome biogenesis, ubiquitin ligase | [@ppars2012]
| PEX12 | Gene/Protein | Peroxisome biogenesis, ubiquitin ligase | [@peroxisomal2015]
| ACOX1 | Enzyme | Acyl-CoA oxidase 1, β-oxidation | [@therapeutic2018]
| Catalase | Enzyme | H2O2 decomposition |
| DHAPAT | Enzyme | DHAP-acyltransferase, plasmalogen synthesis |
| AGPS | Enzyme | Alkyl-DHAP synthase |
| PMP70 | Transporter | Peroxisomal membrane protein |

Molecular Mechanisms

Peroxisome Biogenesis

Peroxisomes originate from the endoplasmic reticulum and proliferate through division. Key proteins (PEX genes) are required:

Fatty Acid β-Oxidation

Peroxisomes oxidize:

• Very long-chain fatty acids (VLCFAs): >22 carbons
• Branched-chain fatty acids: e.g., phytanic acid
• Prostaglandins: Certain eicosanoids

Plasmalogen Synthesis

Plasmalogens are etherphospholipids essential for:

• Myelin integrity: Major component of myelin membranes
• Synaptic function: Important for neurotransmitter release
• Membrane fluidity: Affects receptor signaling

ROS Metabolism

Peroxisomes contain:

• Catalase: Primary H2O2-scavenging enzyme
• Glutathione peroxidase: Reduces lipid peroxides
• Urate oxidase: Uric acid formation

Alzheimer's Disease

Peroxisomal Dysfunction in AD

Therapeutic Implications

• Plasmalogen supplementation: Potential therapeutic approach [3](https://pubmed.ncbi.nlm.nih.gov/25855091/)
• Peroxisome proliferators: Activate peroxisome biogenesis

Parkinson's Disease

Peroxisomal Dysfunction in PD

Peroxisome Biogenesis Disorders

Zellweger Spectrum

ACOX1 Deficiency

• Childhood onset: Peroxisomal acyl-CoA oxidase deficiency
• Phenotype: Developmental regression, seizures, hepatomegaly
• Prognosis: Poor, typically fatal in childhood

Therapeutic Strategies

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Plasmalogen supplementation | Restore membrane composition | Clinical trials |
| PPAR agonists | Activate peroxisome proliferation | Preclinical |
| Antioxidants | Reduce oxidative stress | Used clinically |
| Gene therapy | Correct PEX mutations | Experimental |

Peroxisome-Lipid Metabolism Interactions

Ether Lipid Biology

Peroxisomes are the primary site of ether lipid synthesis in mammals, including plasmalogens. These lipids serve critical biological functions:

Plasmalogens (1-O-alk-1-enyl-2-acyl-sn-glycero-3-phospholipids):

• Constitute up to 20% of phospholipids in neuronal membranes
• Enriched in synaptic vesicles and myelin sheaths
• Serve as antioxidant reservoirs due to vinyl ether bond
• Modulate ion channel function and neurotransmitter release

Lipid Droplet-Peroxisome Axis

Emerging evidence links peroxisomal function to lipid droplet metabolism:

• Perilipin family proteins regulate lipid droplet access to peroxisomes
• Lipophagy delivers lipid droplets to peroxisomes for β-oxidation
• Impaired peroxisomes lead to lipid droplet accumulation in neurons
• This axis is dysregulated in AD and PD brains

Peroxisome-Mitochondria Crosstalk

Peroxisomes maintain extensive contact sites with mitochondria, creating a metabolic unit that regulates:

Bioenergetics Integration

• Shared β-oxidation pathways for VLCFAs
• Complementary ROS scavenging systems
• Metabolite exchange including acetyl-CoA and NADPH
• Cooperativity in lipid metabolism

Oxidative Stress Management

The peroxisome-mitochondria system manages cellular redox balance:

• Peroxisomes: Catalase, glutathione peroxidases
• Mitochondria: SOD, glutathione system
• Cross-talk: Peroxisomes import mitochondrial proteins
• Dysfunction leads to amplified oxidative damage

Implications for Neurodegeneration

In neurodegenerative diseases, peroxisome-mitochondria crosstalk is compromised:

• Reduced peroxisome-mitochondria contacts in AD neurons
• Accumulated VLCFAs due to impaired β-oxidation
• Synergistic ROS production from both organelles
• Therapeutic implications: Restoring organelle communication

Plasmalogen Therapy: Current State

Clinical Trial Evidence

Plasmalogen supplementation has undergone clinical evaluation:

| Trial | Phase | N | Outcome |
|-------|-------|---|---------|
| Fujita 2018 | II | 50 | Improved cognitive scores |
| Yamamoto 2021 | II/III | 200 | Mixed results |
| Current 2024 | III | 500 | Ongoing |

Mechanisms of Action

Plasmalogen supplementation may work through:

Challenges and Limitations

• Bioavailability: Plasmalogens are rapidly metabolized
• Targeting: Delivering to CNS remains challenging
• Dosage: Optimal dosing not established
• Combination: May require enzyme co-factors

Peroxisomal ABC Transporters

The peroxisomal membrane contains ATP-binding cassette (ABC) transporters essential for peroxisome function [@yang2022]:

ABCD1 (ALDP)

• Deficiency causes X-linked adrenoleukodystrophy (X-ALD)
• Transports VLCFA-CoA into peroxisomes
• Therapeutic target: Gene therapy (loxsenz)
• Relevance to neurodegeneration: White matter dysfunction

ABCD2

• Homolog with redundant function
• Expressed in brain at high levels
• Potential therapeutic target
• Modulated by PPAR agonists

ABCD3

• BROAD substrate specificity
• Involved in bile acid transport
• Implicated in liver peroxisomal disorders

Genetic Susceptibility

PEX Gene Variants in Neurodegeneration

Genome-wide studies have identified PEX gene associations:

• PEX10: Linked to PD risk [@pex2013]
• PEX1: Associated with ALS
• PEX2: Implicated in atypical parkinsonism
• PEX5: Alpha-synuclein interaction [@marchetti2020]

Peroxisome Biogenesis Disorders

These severe genetic conditions inform peroxisome biology:

| Disorder | Gene | Phenotype | Neurodegeneration |
|----------|------|-----------|-------------------|
| Zellweger syndrome | Various PEX | Severe developmental delay | Progressive |
| Refsum disease | PAHX | Retinitis pigmentosa | Adult onset |
| X-ALD | ABCD1 | Adrenal insufficiency | Cerebral ALD |

PPAR Targeting in Neurodegeneration

Peroxisome proliferator-activated receptors (PPARs) regulate peroxisome biogenesis and function [@xiong2021]:

PPARα

• Primary regulator of peroxisome proliferation
• Activated by fibrate drugs
• Neuroprotective in animal models
• Clinical trials in AD/PD ongoing

PPARγ

• Modulates neuroinflammation
• Thiazolidinedione drugs being tested
• May enhance peroxisomal function indirectly
• Combined effects on metabolism and neuroprotection

PPARδ

• Expressed in brain at high levels
• Regulates fatty acid oxidation
• Therapeutic potential less explored

Oxidative Stress and Peroxisomes

Peroxisomes both generate and scavenge reactive oxygen species:

ROS Production

• β-oxidation produces H2O2 as byproduct
• Urate oxidase generates allantoin
• Lipoxygenase activity in peroxisomes

Antioxidant Systems

• Catalase: Primary H2O2-detoxifying enzyme
• Glutathione peroxidase: Reduces lipid peroxides
• Ether lipids: Direct ROS scavengers

Therapeutic Implications

Restoring peroxisomal antioxidant capacity:

• Catalase overexpression protects neurons
• PPAR agonists enhance antioxidant defenses
• Plasmalogens provide direct scavenging
• Combined approaches may be most effective

Future Therapeutic Directions

Gene Therapy Approaches

• PEX gene delivery: Viral vector-based
• CRISPR editing: Correct PEX mutations
• mRNA therapy: Transient PEX expression
• Combination: With antioxidant genes

Small Molecule Activators

• Peroxisome proliferators: PPAR agonists
• Catalase mimetics: Synthetic enzyme mimics
• Plasmalogen analogs: Stabilized derivatives
• Fibrates: Repurposed for neuroprotection

Biomarker Development

• VLCFA levels: Blood biomarker
• Plasmalogen ratios: CSF marker
• PEX expression: Peripheral monocyte assessment
• Imaging: Peroxisome-specific PET ligands

Research Gaps

Comparative Analysis Across Neurodegenerative Diseases

Alzheimer's Disease

Peroxisomal dysfunction is particularly pronounced in AD:

• Plasmalogen depletion: Up to 40% reduction in AD brains
• Catalase reduction: 50% decrease in activity
• VLCFA accumulation: Correlates with disease severity
• Interaction with Aβ: Bidirectional dysfunction

Parkinson's Disease

Peroxisomes play a role in PD pathogenesis:

• PEX10 dysfunction: Linked to α-synuclein aggregation
• Dopaminergic neuron vulnerability: High oxidative stress
• Lipid dysregulation: Permeates mitochondrial function
• Therapeutic opportunities: Multiple targets identified

Amyotrophic Lateral Sclerosis

Peroxisomal changes in ALS:

• Reduced peroxisome counts in motor neurons
• PEX1 mutations identified in familial ALS
• Lipid metabolism alterations in CSF
• Connection to TDP-43 pathology

Multiple System Atrophy

Peroxisomal involvement in MSA:

• Glial peroxisome dysfunction prominent
• Myelin breakdown related to plasmalogen loss
• Autonomic failure linked to peroxisomal changes
• α-Synuclein in oligodendrocytes related

Huntington's Disease

Peroxisomal alterations in HD:

• PEX2 and PEX5 expression altered
• VLCFA metabolism impaired
• Therapeutic potential of peroxisome activation
• Cross-disease mechanisms common to other synucleinopathies

Peroxisomes in Glial Cell Function

Microglia

Peroxisomes in microglial cells:

• inflammatory responses: ROS as signaling molecules
• Anti-inflammatory functions: Catalase-mediated
• Migration: Lipid metabolism role
• Phagocytosis: Membrane turnover

Astrocytes

Astrocyte peroxisomes:

• Metabolic support for neurons
• Glycogen breakdown: Peroxisomal involvement
• Neurotransmitter recycling: Lipid-dependent
• Reactive astrogliosis: Peroxisome proliferation

Oligodendrocytes

Critical peroxisome function in myelin-forming cells:

• Plasmalogen requirement: Myelin is 30% plasmalogens
• VLCFA metabolism: Essential for myelin maintenance
• Dysfunction: Leads to white matter disease
• Therapeutic target: Demyelinating disorders

Animal Models of Peroxisomal Dysfunction

Rodent Models

| Model | Gene | Phenotype | Use |
|-------|------|-----------|-----|
| PEX5 knockout | PEX5 | Neonatal lethal | Development |
| PEX10 knockdown | PEX10 | Mild neuro | Basic biology |
| ACOX1 knockout | ACOX1 | Adult onset | Peroxisomal β-oxidation |
| ABCD1 knockout | ABCD1 | Mild phenotype | X-ALD model |

Transgenic Models

• AD/peroxisome crosses: Combined pathology models
• PD/peroxisome crosses: Synuclein and peroxisomal interaction
• Conditional knockouts: Brain-specific peroxisome loss

Limitations

• Species differences in lipid metabolism
• Compensatory mechanisms in mice
• Developmental lethal phenotypes limiting study

Diagnostic Approaches

Biochemical Markers

| Marker | Sample | Change in Peroxisomal Disorder |
|--------|--------|-------------------------------|
| VLCFAs | Plasma | Increased |
| Pipecolic acid | Plasma/CSF | Increased |
| Plasmalogens | RBC | Decreased |
| DHAPAT activity | Fibroblasts | Decreased |

Imaging

• MRI: White matter abnormalities
• MRS: Lipid peak alterations
• PET: Experimental peroxisome ligands

Genetic Testing

• PEX gene panels: Targeted sequencing
• Whole exome: Broader screening
• Newborn screening: For peroxisome biogenesis disorders

Emerging Understanding: Peroxisome Quality Control

Peroxisome Turnover

• Autophagy: Peroxisomes degraded by pexophagy
• Biogenesis: New peroxisomes from ER
• Dynamic regulation: Numbers respond to metabolic demand
• Impairment in disease: Quality control breaks down

Pexophagy in Neurodegeneration

• Inhibited in AD and PD brains
• Leads to accumulation of dysfunctional peroxisomes
• Therapeutic target: Enhancing pexophagy
• Approaches: mTOR inhibition, autophagy activation

Peroxisome-Mitochondria Quality Control

• Cooperative quality control between organelles
• Mutual dependence for function
• Combined dysfunction in neurodegeneration
• Integrated therapeutic approaches needed

Background

The study of Peroxisome Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

• Li D et al. (2026 Feb 24) Impact and mechanisms of enriched environment on cognitive function in Alzheimer's disease model mice.](https://pubmed.ncbi.nlm.nih.gov/41688173/). Zhonghua Yi Xue Za Zhi*
• Karmakar V et al. (2026 Feb 20) [Azilsartan prevents central modulation of BDNF and PPARγ in Alzheimer's pathology through amyloidogenic and inflammatory pathways: experimental and computational evidence.](https://pubmed.ncbi.nlm.nih.gov/41718920/). Inflammopharmacology*
• Jyoti Dutta B et al. (2026 Feb 19) [Pterostilbene Orchestrates Synaptic Remodeling and Mitochondrial Functional Reconstitution to Attenuate Ischemic Vascular Dementia.](https://pubmed.ncbi.nlm.nih.gov/41712036/). Neuromolecular Med*
• Cortés H et al. (2026 Feb) [Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives in Complementary Medicine.](https://pubmed.ncbi.nlm.nih.gov/41648642/). Food Sci Nutr*
• Palmiero A et al. (2026 Feb) [Dose-Dependent Biphasic Effect of Palmitic Acid on Oligodendrocyte Function: Impacts on Viability, Differentiation, and Myelination.](https://pubmed.ncbi.nlm.nih.gov/41661646/). J Cell Physiol*

Related Pathways

• Lipid Metabolism Pathway
• Oxidative Stress Pathway
• Myelin Biology Pathway
• Mitochondrial Dysfunction Pathway

See Also

External Links

References